Edwards Lifesciences (NYSE:EW) Given New $101.00 Price Target at Barclays

Edwards Lifesciences (NYSE:EW) had its price objective increased by Barclays from $100.00 to $101.00 in a report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Other equities research analysts have also recently issued reports about the stock. StockNews.com raised shares of Edwards Lifesciences from a hold rating to a buy rating in a research report on Monday, April 29th. Evercore ISI decreased their price target on Edwards Lifesciences from $92.00 to $89.00 and set an in-line rating for the company in a report on Friday, April 26th. Oppenheimer increased their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an outperform rating in a report on Monday, March 18th. Citigroup boosted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a neutral rating in a research note on Wednesday, April 3rd. Finally, Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a hold rating in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $93.27.

Edwards Lifesciences Stock Up 0.9 %

Shares of NYSE:EW opened at $85.85 on Tuesday. The firm’s 50-day moving average is $90.05 and its two-hundred day moving average is $79.69. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12. The firm has a market capitalization of $51.73 billion, a PE ratio of 37.00, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Analysts predict that Edwards Lifesciences will post 2.77 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $86.67, for a total value of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now owns 4,486 shares in the company, valued at approximately $388,801.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bernard J. Zovighian purchased 580 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was bought at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders sold a total of 237,749 shares of company stock worth $20,920,934 in the last ninety days. Insiders own 1.27% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several large investors have recently bought and sold shares of EW. Riverview Trust Co acquired a new stake in Edwards Lifesciences during the 1st quarter valued at $34,000. DSM Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $34,000. Rise Advisors LLC boosted its holdings in Edwards Lifesciences by 125.0% in the first quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 265 shares during the last quarter. Finally, Pingora Partners LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.